Vol. 7, No. 1 (2018) | ISSN 2166-7403 (online) DOI 10.5195/cajgh.2018.295 | http://cajgh.pitt.edu
The WHO Health Emergencies Programme is currently monitoring 118 events in the region. This week’s main articles cover the following events:
Coronavirus disease 2019 (COVID-19) in Togo
Measles in Chad
Ebola virus disease (EVD) in Équateur Province, Democratic Republic of the Congo.
Основная цель этого Руководства состоит в том, чтобы очертить рамки методов, используемых для оценки распространенности ВИЧ-инфекции среди больных туберкулезом и... способствовать осуществле-нию эпиднадзора за ВИЧ-инфекцией.
more
Vol. 7, No. 1 (2018) | ISSN 2166-7403 (online) DOI 10.5195/cajgh.2018.295 | http://cajgh.pitt.edu
Working Document - Updated -February 2009
July 2019
Policy brief
HIV Treatment
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
BMC Public Health (2016) 16:766
DOI 10.1186/s12889-016-3455-5
Policy brief.
HIV self-testing (HIVST) is a convenient and confidential option for HIV testing. In 2016 WHO recommended HIVST as a safe, accurate and effective way to reach people who may not test otherwise, including people from key populations, men and young people. Lay users can perform HIVST r...eliably and accurately and achieve performance comparable to that of trained health-care workers.
Globally, many countries have developed HIVST policies, and implementation is growing rapidly. This policy brief highlights new guidance to optimize HIVST implementation, including effective service delivery models, linkage to care and support tools.
more